drugset
drugset / Trial / NCT04534634

Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia（R/R-ALL）

NCT04534634 ↗

Phase 2 Unknown 60 enrolled The First Affiliated Hospital of Soochow University
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of IFN-α combined with CAR-T cell therapy in relapsed and refractory acute lymphoblastic leukemia (R/R ALL).

Timeline

Start
2019-04-01
Primary completion
2023-07-31
Completion
2025-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Axicabtagene Ciloleucel Cell therapy 1e+07 cells/kg Intravenous
Subject Axicabtagene Ciloleucel Cell therapy 2e+07 cells/kg Intravenous
Subject Interferon-α Protein / enzyme biologic 200 mg/m2 Intramuscular
Subject Interferon-α Protein / enzyme biologic 3e+08 iu Intramuscular

Indications

B-cell acute lymphoblastic leukemia